Neobe Therapeutics develops programmable microbial trojan horses using a synthetic biology platform. These engineered live biotherapeutics are designed to disrupt the microenvironment of solid tumors. This approach aims to enable successful immunotherapy in patients with immune-excluded tumors.
Funding
$2.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumors often create a microenvironment that excludes immune cells and limits drug penetration, reducing the effectiveness of immunotherapies and other cancer treatments. This immune exclusion prevents many patients from responding to therapies and contributes to treatment resistance.
Solution
Neobe Therapeutics is developing a synthetic biology platform to engineer live bacterial therapeutics that selectively colonize solid tumors and remodel their microenvironment. By modifying the tumor microenvironment, the engineered bacteria enhance immune cell infiltration and drug delivery, increasing the efficacy of existing immunotherapies. This approach aims to overcome immune exclusion and improve treatment outcomes for patients with previously non-responsive tumors, while minimizing systemic toxicities.
Target Audience
The primary target audience includes oncology researchers, pharmaceutical companies developing immunotherapies, and clinicians treating patients with solid tumors that are resistant to current treatments.
Features
- Engineered live bacterial products (LBPs) designed to selectively colonize solid tumors.
- Synthetic biology platform for programming bacteria to disrupt the tumor microenvironment.
- Enhanced immune cell infiltration into tumors through microenvironment remodeling.
- Increased drug delivery to tumors, improving the efficacy of existing therapies.
- Targeted approach to minimize systemic toxicities and improve patient outcomes.